Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report

被引：4

作者：

Kattan, Joseph ^{[1
]}

Kattan, Clarisse ^{[1
]}

Farhat, Fadi ^{[2
]}

Assi, Tarek ^{[2
,3
]}

机构：

[1] St Joseph Univ, Hotel Dieu France Univ Hosp, Hematol Oncol Dept, Fac Med, Beirut, Lebanon

[2] Hammoud Hosp UMC, Hematol Oncol Dept, Saida, Lebanon

[3] St Joseph Univ, Hematol Oncol Dept, Fac Med, Beirut, Lebanon

来源：

ANTI-CANCER DRUGS | 2019年 / 30卷 / 10期

关键词：

binimetinib; BRAF; encorafenib; immune checkpoint; MEK; melanoma; resistance; METASTATIC MELANOMA; MUTANT MELANOMA; OPEN-LABEL; NIVOLUMAB; COMBINATION; DABRAFENIB; TRAMETINIB; IPILIMUMAB; EFFICACY; STANDARD;

D O I：

10.1097/CAD.0000000000000827

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The advent of BRAF and MEK inhibitors changed the landscape of the management of BRAF mutated melanoma patients. In this article, we report the case of a 51-year-old man with BRAF mutated locally advanced cutaneous melanoma of the head who demonstrated a limited response to initial anti-BRAF monotherapy followed by extensive surgery. Anti-PD1 therapy failed to reverse the disease progression. However, subsequent double inhibition of the BRAF and MEK pathways induced a fast and remarkable tumour response.

引用

页码：1052 / 1054

页数：3

共 50 条

[1] BRAF/MEK inhibitor rechallenge in advanced melanoma patients
Van Not, Olivier J.
van den Eertwegh, Alfons J. M.
Haanen, John B.
van Rijn, Rozemarijn S.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
Blank, Christian U.
Boers-Sonderen, Marye J.
de Groot, Jan Willem W. B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Bloem, Manja
Piersma, Djura
Stevense-den Boer, Marion
Verheijden, Rik J.
van der Veldt, Astrid A. M.
Wouters, Michel W. J. M.
Blokx, Willeke A. M.
Suijkerbuijk, Karijn P. M.
CANCER, 2024, 130 (09) : 1673 - 1683
[2] BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
Richman, Juliet
Martin-Liberal, Juan
Diem, Stefan
Larkin, James
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (09) : 1285 - 1297
[3] BRAF and MEK inhibition in melanoma
Dossett, Lesly A.
Kudchadkar, Ragini R.
Zager, Jonathan S.
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (04) : 559 - 570
[4] BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma
Queirolo, Paola
Spagnolo, Francesco
CANCER AND METASTASIS REVIEWS, 2017, 36 (01) : 35 - 42
[5] BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy
Johnson, Douglas B.
Childress, Merrida A.
Chalmers, Zachary R.
Frampton, Garrett M.
Ali, Siraj M.
Rubinstein, Samuel M.
Fabrizio, David
Ross, Jeffrey S.
Balasubramanian, Sohail
Miller, Vincent A.
Stephens, Philip J.
Sosman, Jeffrey A.
Lovly, Christine M.
PIGMENT CELL & MELANOMA RESEARCH, 2018, 31 (03) : 432 - 436
[6] The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era
Vanella, Vito
Festino, Lucia
Trojaniello, Claudia
Vitale, Maria Grazia
Sorrentino, Antonio
Paone, Miriam
Ascierto, Paolo A.
CURRENT ONCOLOGY REPORTS, 2019, 21 (09)
[7] Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development of BRAF inhibitor resistance
Martin, Claire A.
Cullinane, Carleen
Kirby, Laura
Abuhammad, Shatha
Lelliott, Emily J.
Waldeck, Kelly
Young, Richard J.
Brajanovski, Natalie
Cameron, Donald P.
Walker, Rachael
Sanij, Elaine
Poortinga, Gretchen
Hannan, Ross D.
Pearson, Richard B.
Hicks, Rodney J.
McArthur, Grant A.
Sheppard, Karen E.
INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (10) : 2139 - 2152
[8] Why do we need a new BRAF-MEK inhibitor combination in melanoma?
Kozak, Katarzyna
Rutkowski, Piotr
ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (02): : 115 - 119
[9] Overcoming resistance to BRAF inhibitors
Arozarena, Imanol
Wellbrock, Claudia
ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (19) : 1 - 12
[10] Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
Spagnolo, Francesco
Ghiorzo, Paola
Queirolo, Paola
ONCOTARGET, 2014, 5 (21) : 10206 - 10221

← 1 2 3 4 5 →